- Global Pharma News & Resources

Lewy Body Dementia Treatment Market Size to touch US$ 5.15 Billion by 2025 at a CAGR of 6%

Noida, Uttar Pradesh, India, February 22 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global Lewy body dementia treatment Market is estimated to see healthy growth, pegged at a CAGR of ~6% during the forecast period 2020-2025. The rise in government initiatives to generate awareness about lewy body dementia treatment is probable to uphold the market’s growth. For instance, the US has signed into law the BOLD Infrastructure for Alzheimer’s Act, an initiative to form a public health model against Alzheimer’s disease and other dementias. The law would sanction around USD 100 million over the upcoming five years to improve public education, strengthen numerous dementia initiatives being taken by various social and health service agencies, and collect & allocate data related to cognitive decline. Moreover, the increase in the development funding has been reinforced to promote the treatment and create awareness for the lewy body dementia treatment by the novel R&D initiative by the National Institutes of Health (NIH).

Download Report Sample PDF @

The increasing lewy body dementia prevalence and the limited presence of concerned drugs to manage this illness further influence pharma companies to invest in R&D activities that are focused globally. Currently, Alzheimer’s treatment drugs are used to manage lewy body dementia; however, a range of generic drugs will probably proliferate the market in the coming years.

The high lewy body dementia treatment cost has prompted healthcare providers to bring certain aspects under the ambit of reimbursements. Favorable regulations about lewy body dementia treatment have meant that economically weaker sections of the society have access to quality care, which has opened up pharmaceutical companies’ opportunities. However, the burgeoning number of performed clinical trials for lewy body dementia treatment underpins gains in the market by bolstering the existing treatment options’ efficiency. The growth in ongoing treatment trials for improved lewy body dementia medication has the great potential to drive market growth substantially and further provided these trials result in successful outcomes that will lead to the new demand in the end-use market.

North America is forecasted to take the significant lead in the global lewy body dementia treatment market in 2019. The rise in brain-related disorder cases, implementation of relevant dementia drug procedures, availability of improved healthcare facilities, and favorable reimbursement policies has created the scope for tremendous growth in the region. Moreover, the presence of a large geriatric population, growing investments in R&D activities, and improving accessibility to dementia treatments further enhance the lewy body dementia treatment demand.

Allergan Plc., Mallinckrodt Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Sanofi AG, BioArctic AB, Teva Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Mylan NV, Bayer AG, and Bausch Health Companies Inc., among others, are some crucial players included in the research study of the global lewy body dementia treatment market.


Drug Type (Modafinil, Cholinesterase Inhibitors, Benzodiazepine, Antipsychotic Drugs, Antidepressants, Carbidopa-Levodopa)

Indication (Parkinson’s Disease, Dementia with Lewy Bodies (DLB))

Distribution Channel (Drug Stores, Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies)

By Region (Americas North America The U.S. Canada Mexico South America Brazil Rest of South America Europe Germany The U.K. France Rest of Europe Asia Pacific Japan China India Rest of Asia Pacific Middle East & Africa)

For Purchase Enquiry @

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 22-Feb-2021